SEE THE RDN PROCEDURE

This short animation shows how the Medtronic Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter positions electrodes to generate 360 degrees of ablation. As a result, the catheter can treat the distal branches to maximize the probability of complete denervation.

PROCEDURAL STEPS FOR RDN

Step One Icon

An interventional catheter (described to patients as a thin tube) is inserted into the renal arteries.

Step Two Icon

The catheter is kept in place for one minute at a time, delivering energy to help regulate overactive nerves.

Step Three Icon

Typically, the interventional physician will treat multiple portions of the renal artery.

Step Four Icon

The procedure is performed in all accessible renal arteries.

Step Five Icon

Following treatment, the catheter is removed  and no permanent implant is left behind.

RDN IS SHOWN TO REDUCE BLOOD PRESSURE

Medtronic has investigated RDN's blood-pressure-lowering effect in three randomized, sham-controlled studies and in the Global Symplicity Registry (GSR), which showed positive outcomes in real world-patients and sustained blood pressure reductions through three years among the largest follow-up group of any RDN study with 2,800 patients enrolled in 42 countries.

The development of the Medtronic Symplicity Spyral™ Renal Denervation System, including the Symplicity Spyral™ Catheter and the Symplicity G3™ Renal Denervation RF Generator, are the culmination of 12 years of rigorous scientific development.1

  • More than 6,000 completed procedures and three years of real-world registry results2
  • Most patients experience lower blood pressure1,3
  • No major adverse events were reported in HTN-ON MED or HTN-OFF MED clinical studies through six and three months, respectively.1,3,5
A graphic showing that more than 12,000 patient-years followed up.

Advances in Renal Denervation (20:13)

Dr. Andrew Sharp discusses recent innovations in the renal denervation (RDN) procedure, focusing on radiofrequency ablation as the tool for delivering energy to the renal sympathetic nerve.
More information (see more) Less information (see less)

RDN PATIENT SELECTION

Who is a candidate for the Medtronic Symplicity Spyral™ RDN system?

SEE THE CRITERIA

Let's Fight Hypertension Together

Access support resources for getting started with RDN.

CONTACT US
1

Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-2355.

2

Medtronic Global Symplicity Registry.

3

Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–2170

4

As of August 2018, Medtronic data on file.

5

As of August 2018, Medtronic safety data on file.

All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.  For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France.